Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease "DECISIVE"


Phase 4 Results N/A

Summary of Purpose

The prevalence of AF, which is tachyarrhythmia, is approximately 2% of the entire population and 5% of the population at the age of 60 or older. AF is the cause of approximately 20% of all events of ischemic stroke, and patients with AF are known to be at 6 to 10% risk of ischemic stroke per year. Patients with valvular AF are known to have a higher incidence of stroke than patients with nonvalvular AF. However,...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 8 January 2018.

1 Dec 2016 29 Nov 2016 1 Dec 2019 1 Dec 2019 1 Jan 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available